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Abstract
Hepatitis C virus (HCV) infected patients with vasculitis are often treated with the B-cell-depleting anti-CD20 antibody
rituximab. Treatment reduces the cryoglobulins that cause vasculitis, yet it also leads to a transient increase in liver enzymes
and HCV genomic RNA in the periphery. The mechanism underlying the increased viral load is unclear and both direct and
indirect roles have been proposed for B cells in HCV infection. We previously reported that HCV can associate with B cells
and can trans-infect hepatocytes. We established an in vitro assay to study the effect(s) of rituximab on B cell-associated HCV
infectivity. Rituximab-mediated lysis of B cells in vitro increases the level of infectious HCV released from B cells. Our results,
using a model where virus does not replicate in B cells, recapitulate observations seen in patients and may explain in part
the rapid increase in blood HCV RNA observed after rituximab treatment.
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Introduction
HCV infection predominantly affects the liver but extrahepatic
manifestations have been reported [1,2]. Patients who present with
symptoms of vasculitis caused by type II cryoglobulinaemia can
benefit from treatment with the chimeric monoclonal anti-CD20
antibody rituximab, which depletes B cells in the circulation.
Rituximab was first developed to target malignant B cells [3,4].
Pre-B cells, immature, mature and activated B cells all express
CD20 and are susceptible to antibody-dependent lysis [5]. In
contrast, hematopoietic progenitor cells, pro-B cells and differen-
tiated antibody-producing plasma cells do not express CD20 and
are insensitive to rituximab: the distribution of CD20 allows for a
reversible effect and has no influence on high affinity class-
switched antibodies [6].
The main modes of rituximab action include antibody-
dependent cellular cytotoxicity (ADCC) and complement-depen-
dent cytotoxicity (CDC) (Figure 1), however, apoptosis and
phagocytosis have been implicated in B cell depletion [7,8,9].
Treatment reduces the level of antibodies that drive cryoglobulin
formation and alleviates the clinical symptoms of vasculitis, yet
treatment is often associated with a transient increase in liver
enzymes and peripheral HCV viral load [10,11].
It has been challenging to demonstrate that HCV replicates in B
cells [12] and recent reports suggest that the JFH-1 strain of HCV
that replicates in cell culture (HCVcc) [13,14,15] does not
productively infect lymphocytes [16,17]. We recently demonstrat-
ed that although B cells do not support HCV replication they can
bind HCVcc and trans-infect hepatocytes [17].
Lake-Bakaar and colleagues studied HCV kinetics in infected
patients treated with rituximab [10]. The re-appearance of B cells
following treatment coincided with a decrease in viral load,
suggesting that B cells may serve a protective role. It is not clear
why B cell depletion would lead to an increase in peripheral
HCV RNA and direct and indirect roles have been proposed for
B cells in controlling infection. To address this question, we
established an in vitro ADCC model to study the effects of
rituximab on B cell associated HCV. We used NK cell
degranulation as an indirect measure of cytotoxicity induced by
rituximab, and determined the amounts of infectious virus shed
by the target B cells. This system revealed that B cells lysed in a
rituximab-dependent manner could release a substantial amount
of infectious HCV.
Materials and Methods
Primary cells, cell lines and viruses
Peripheral blood mononuclear cells (PBMC) were isolated from
whole blood by density gradient centrifugation from healthy
volunteers who gave informed written consent for participation in
the study according to the Declaration of Helsinki. Ethical
approval was obtained by the South Birmingham Local Research
Ethics Committee (Queen Elizabeth Hospital, Birmingham, UK)
and the University Hospital Birmingham Trust. We used the
Group I Burkitt’s lymphoma B cell line L3055 as a target for the
ADCC assay (a kind gift from Prof. J. Gordon, University of
Birmingham) and Jurkat T cells as controls (ATCC). Cells were
isolated and/or propagated as described [17]. HCVcc JFH-1 was
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permissive Huh-7 hepatoma cell line was used to measure
infectious HCV.
ADCC assay
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24 hours to stimulate Natural Killer (NK) cells. Target L3055 B
cells were incubated with HCVcc JFH-1 for 2 hours, unbound
virus was removed by extensive washing and the cells were then
treated with rituximab or control antibody at 10 mg/ml for 30
minutes. Activated PBMC were co-cultured with target cells at
1:10 effector:target (E:T) ratio for 3-7 hours. Rituximab activity
was measured by a flow cytometric CD107a NK cell degran-
ulation assay [18]. B cell lysis was confirmed by trypan blue
uptake.
Statistical analysis
Data were presented as means from three or four replicates.
Error bars represent standard deviations and comparisons
between samples were made using nonparametric tests (Mann-
Whitney for unpaired samples and Wilcoxon for paired samples)
using Prism 4.0 (GraphPad Software, San Diego, CA).
Results
To mimic the effects of rituximab on CD20+ Bc e l ld e p l e t i o n
by blood cells, we used PBMC from healthy donors as effectors
and the Burkitts lymphoma B cell line L3055 as target cells. We
previously reported that B cells bound optimal levels of HCV
after 2 hours [17], we therefore incubated target B cells with
HCVcc JFH-1, washed extensively to remove non-associated
virus and treated with rituximab or control antibody at 10 mg/ml.
Resting or IL-2 (100 IU/ml) stimulated PBMC were incubated
with the target cells at a ratio of 1:10 for the times indicated in
Figure 2. Successful effector activation by rituximab was
measured by a flow cytometry-based assay that measures NK
cell activation as a factor of CD107a degranulation (Figure 2A).
The specificity of rituximab was confirmed using Jurkat T cells as
targets, which do not express CD20 (data not shown). As
expected, IL-2 pre-treatment of PBMC increased NK cell
degranulation and CD107a expression (Figure 2A). Rituximab
treatment consistently induced approximately 60% of NK cells to
degranulate, independent of PBMC donor variations (data not
shown).
We sampled the extracellular media from the ADCC assay for
infectious virus released by the lysed target B cells over time
(Figure 2B). There was a significant increase in the level of
infectious virus after 4 hours of ADCC (p=0.0442), which
coincided with effective B cell lysis. One consequence of the in
vitro ADCC assay where target cells are lysed, would be the
release of soluble factors that may affect HCV infectivity. It was
therefore important to determine the effect(s) of ADCC-mediated
soluble factors on HCV infectivity; to this effect, we performed
independent ADCC assays in the presence of HCVcc JFH-1 and
compared its infectivity to input virus (Figure 2C). Our findings
demonstrate that HCV infectivity was not affected by the
presence of PBMC/L3055 co-cultures with rituximab or control
antibody.
Discussion
For these experiments, we used HCVcc JFH-1, a genotype 2a
strain that replicates in hepatocytes in vitro and in vivo but does
not replicate in B cells. Despite the lack of productive infection,
our study demonstrated that B cells lysed by effector blood cells
could release up to four times more infectious virus following
rituximab treatment.
Use of primary B cells from peripheral blood of healthy donors
as targets instead of L3055 cells yielded comparable results (data
not shown), however this may not reflect the ability of B cells in
vivo to capture virus. It is worth noting that L3055 B cells used as
rituximab targets, as well as B cells from healthy donors, were not
specific for HCV; indeed we previously demonstrated that
primary PBMC-derived B cells and L3055 cells bind comparable
amounts of HCVcc RNA as measured by quantitative RT-PCR
[17]. This was in the order of ,2,000 RNA copy numbers
per 106 B cells (or L3055 B cells), which was relatively low
compared to the ,55,000 RNA copy numbers per 106
permissive Huh-7.5 cells. This study demonstrated virus interac-
tion with B cell-expressed C-type lectins DC-SIGN (dendritic
cell–specific ICAM-3–grabbing nonintegrin) and L-SIGN (liver/
lymph node–specific ICAM-3–grabbing nonintegrin), and the
scavenger receptor class B member I (SR-BI). C-type lectins were
expressed in a small B cell subset, whereas SR-BI was present on
all B cells. The ability of different B cell subsets to capture HCV
remains to be defined.
Our in vitro ADCC assay does not take into account potential
virus replication in B cells that may occur in vivo, or the role of B
cells in controlling infection via immune protection or indirect
clearance mechanisms; despite these limitations, we demonstrated
a significant increase in the level of infectious HCV released from
B cells in the presence of rituximab which may contribute to the
increased viral load observed in patients. In summary, our data
support a role for rituximab lysis of B cells and release of infectious
HCV as a mechanism to explain the transient increase in viral
load observed in treated patients.
Figure 1. Rituximab mode of action. Rituximab is a monoclonal
antibody that recognises the transmembrane receptor CD20 on B cells.
Patient treatment with rituximab results in rapid depletion of CD20+ B
cells from the circulation, where B cells are deleted predominantly via
antibody-mediated and complement-dependent cytotoxicity (ADCC
and CDC respectively). NK cells are thought to be the major ADCC-
mediating effector cells.
doi:10.1371/journal.pone.0025789.g001
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